Interleukin-33 (IL-33): a critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine.

Cayrol C, Girard JP. Cytokine. 2022;156(155981):1-15.

Reduction in exacerbations with itepekimab in former smokers with chronic obstructive pulmonary disease (COPD) by prior exacerbation frequency.

Rabe KF, et al. Eur Respir J. 2024;64(suppl 68):OA3645.

Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.

Rabe KF, et al. Lancet Respir Med. 2021;9(11):1288-1298.

Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD

Calderon AA, et al. Eur Respir Rev. 2023;32(167):220144.

Involvement of IL-33 in the pathogenesis and prognosis of major respiratory viral infections: future perspectives for personalized therapy.

Murdaca G, et al. Biomedicines. 2022;10(3):715.

IL-33 and the cytokine storm in COVID-19: from a potential immunological relationship towards precision medicine.

Furci F, et al. Int J Mol Sci. 2022;23(23):14532.

Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial.

Yousuf AJ, et al. Lancet Respir Med. 2022;10(5):469-477.

A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4.

Singh D, et al. Eur Respir J. 2025;66(1):2402231.

Late-Breaking Abstract. Randomised, placebo-controlled trial of astegolimab for COPD with frequent exacerbations: ALIENTO.

Greening N, et al. Eur Respir J. 2025;66(suppl 69).

Efficacy and safety of itepekimab in former smokers with chronic obstructive pulmonary disease: AERIFY-1 and AERIFY-2 Trials.

Rabe KF, et al. Presented at: American Thoracic Society (ATS) 2026 International Conference; May 15-20, 2026; Orlando, FL.